Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced Esophageal Cancer

NCT05349045 · clinicaltrials.gov ↗

UNKNOWN

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Neoplasms

Interventions

DRUG: an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor

Sponsor

The First Affiliated Hospital of Zhengzhou University